tagrisso
astrazeneca ab - osimertinib mesilate - rak, niedrobnokomórkowe płuca - inne leki przeciwnowotworowe, inhibitory białka kinazy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
cotellic
roche registration gmbh - hemifumaran cobimetinibu - czerniak - Środki przeciwnowotworowe - cotellic jest wskazany do stosowania w skojarzeniu z wemurafenibem w leczeniu dorosłych pacjentów z nieoperacyjnym lub przerzutowym czerniakiem z mutacją braf v600.
tafinlar
novartis europharm limited - dabrafenib mesilate - czerniak - Środki przeciwnowotworowe - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. leczenie uzupełniające melanomadabrafenib w połączeniu z trametinib wskazany dla adjuvant leczenia dorosłych pacjentów z iii stadium czerniaka z brugh mutacja v600 daleko, po całkowitej resekcji. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
mekinist
novartis europharm limited - trametynib - czerniak - Środki przeciwnowotworowe - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 i 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. niedrobnokomórkowego raka płuca (nsclc)trametinib w połączeniu z dabrafenib jest wskazany do leczenia dorosłych pacjentów z postępowym małym komórka nowotworem płuc z brugh mutacja v600 daleko .
orungal 100 mg kapsułki
janssen-cilag international n.v. - itraconazolum - kapsułki - 100 mg
itromyx 100 mg kapsułki twarde
adamed pharma s.a. - itraconazolum - kapsułki twarde - 100 mg
voriconazol polpharma 200 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - voriconazolum - tabletki powlekane - 200 mg
voriconazole sandoz 200 mg tabletki powlekane
sandoz gmbh - voriconazolum - tabletki powlekane - 200 mg
voriconazole sandoz 200 mg proszek do sporządzania roztworu do infuzji
sandoz gmbh - voriconazolum - proszek do sporządzania roztworu do infuzji - 200 mg
zejula
glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - Środki przeciwnowotworowe - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.